4-(4-甲基苯氧基)丁酰氯 | 71720-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4-甲基苯氧基)丁酰氯
• 英文名称: (4-chloro-butyl)-p-tolyl ether
• 英文别名: (4-Chlor-butyl)-p-tolyl-aether；1-(4-chlorobutoxy)-4-methylbenzene；1-(4-methylphenoxy)-4-chlorobutane
• CAS: 71720-44-0
• 化学式: C₁₁H₁₅ClO
• 分子量: 198.692
• InChiKey: VWDLBAQKWPLCJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  4-(4-甲基苯氧基)丁酰氯 在 盐酸 、 聚合甲醛 、 1,2-二氯乙烷 作用下， 生成 (4-chloro-butyl)-(2-chloromethyl-4-methyl-phenyl)-ether
  参考文献：
  名称：

  Macro Rings Containing Carbon, Oxygen and Sulfur

  摘要：

  DOI：

  10.1021/jo01354a004
• 作为产物：
  描述：

  sodium 4-methylphenoxide 、 1,4-二氯丁烷 在 乙醇 作用下， 生成 4-(4-甲基苯氧基)丁酰氯
  参考文献：
  名称：

  Phenoxy- and Benzyloxyalkyl Thiocyanates¹

  摘要：

  DOI：

  10.1021/ja01151a047

文献信息

• Heterocyclic compounds for treating myocardial ischemia
  申请人：Pierre Fabre Medicament

  公开号：US06011032A1

  公开（公告）日：2000-01-04

  Substituted N-heterocyclyl-1-aryloxyalkyl-4-piperldineamines of formula (I) ##STR1## wherein each of R.sub.1 to R.sub.4, which are the same or different, is hydrogen, optionally branched C.sub.1-4 alkyl, optionally branched C.sub.1-4 alkyloxy, halo, nitro, hydroxy, or trifluoromethyl or trifluoromethoxyl; R.sub.5 is hydrogen, optionally branched C.sub.1-6 alkyl, optionally branched C.sub.7-12 phenylalkyl optionally substituted on the phenyl by one or more radicals having the same definition as R.sub.1 ; W and X are oxygen or sulphur; Y is C.sub.2-6 polymethylene or --CH.sub.2 --CH(OH)--CH.sub.2 --; and n is 0 or 1; and pure R or S isomers of said compounds, where applicable, as well as mixtures thereof, as well as therapeutically-acceptable organic or inorganic salts and hydrates of the compounds and a method for preparing the compounds and their use as drugs are all disclosed.

  化学式（I）中的N-杂环基-1-芳氧基烷基-4-哌啶胺衍生物，其中R.sub.1到R.sub.4中的每个，它们相同或不同，是氢、可选择性支链的C.sub.1-4烷基、可选择性支链的C.sub.1-4烷氧基、卤素、硝基、羟基、三氟甲基或三氟甲氧基；R.sub.5是氢、可选择性支链的C.sub.1-6烷基、可选择性支链的C.sub.7-12苯基烷基，可选择性在苯基上用一个或多个具有与R.sub.1相同定义的基团取代；W和X是氧或硫；Y是C.sub.2-6聚亚甲基或--CH.sub.2--CH(OH)--CH.sub.2--；n为0或1；以及所述化合物的纯R或S异构体（如适用），以及它们的混合物，以及所述化合物的治疗上可接受的有机或无机盐和水合物，以及制备所述化合物的方法和它们作为药物的用途均已披露。
• Carboline Derivatives Useful in the Inhibition of Angiogenesis
  申请人：MOON Young-Choon

  公开号：US20070281962A2

  公开（公告）日：2007-12-06

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

  根据本发明，已经鉴定出了抑制VEGF转录后表达的化合物，并提供了它们的使用方法。在本发明的一个方面，提供了在抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性方面有用的化合物。在本发明的另一个方面，提供了使用本发明中的化合物抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的方法。
• PHENYLPYRAZOLE DERIVATIVES
  申请人：NAKAMURA Toshio

  公开号：US20110065667A1

  公开（公告）日：2011-03-17

  The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 , which may be the same or different, each represent C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, or R 1 and R 2 are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C 1 -C 6 alkyl), n represents an integer of 0 to 2, T represents a hydrogen atom, halogen or C 1 -C 6 alkyl, and R represents formula (I): or the like}.

  本发明提供一种预防或治疗痴呆症、阿尔茨海默病、注意力缺陷多动障碍、精神分裂症、进食障碍、肥胖症、糖尿病、高脂血症、睡眠障碍、嗜睡症、睡眠呼吸暂停综合症、昼夜节律紊乱、抑郁症、过敏性鼻炎或其他疾病的预防或治疗剂。该预防或治疗剂为一种苯基吡唑衍生物，其化学式为（1），或其药学上可接受的盐：其中，R1和R2分别表示C1-C6烷基或C3-C8环烷基，或者R1和R2与它们相邻的氮原子一起连接形成4-至7-成员饱和杂环环（其中，所述饱和杂环环可以被卤素或C1-C6烷基取代），n表示0至2的整数，T表示氢原子、卤素或C1-C6烷基，R表示式（I）或类似物}。
• CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
  申请人：Moon Young-Choon

  公开号：US20100179132A1

  公开（公告）日：2010-07-15

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

  根据本发明，已经鉴定出抑制VEGF在转录后表达的化合物，并提供了它们的使用方法。本发明的一方面提供了用于抑制VEGF生产、治疗实体肿瘤癌和减少血浆和/或肿瘤VEGF水平的化合物。本发明的另一方面提供了使用本发明中的化合物抑制VEGF生产、治疗癌症和减少血浆和/或肿瘤VEGF水平的方法。
• METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0937703A1

  公开（公告）日：1999-08-25

  The present invention is directed to a method for purifying pyruvic acid compounds, which method comprises reacting a pyruvic acid compound of general formula (I): wherein R1 is an optionally substituted lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and R2 is a lower alkyl group, with a bisulfite of general formula (II):         MHSO3     (II) wherein M is NH4 or an alkali metal, to give a bisulfite adduct of the pyruvic acid compound and then decomposing the adduct with an acid. According to the present invention, pyruvic acid compounds can be purified by simple and easy procedures without using purification techniques such as distillation or column chromatography, and the above method is advantageous as a process for the production on an industrial scale.

  本发明涉及一种纯化丙酮酸化合物的方法，该方法包括使通式(I)的丙酮酸化合物反应： 其中 R1 是任选取代的低级烷基、低级烯基、低级炔基、环烷基、芳基或杂环基，R2 是低级烷基，与通式（II）的亚硫酸氢盐反应： MHSO3 (II) 其中 M 为 NH4 或碱金属，以得到丙酮酸化合物的亚硫酸氢盐加合物，然后用酸分解该加合物。根据本发明，丙酮酸化合物可以通过简单易行的程序进行纯化，而无需使用蒸馏或柱层析等纯化技术，上述方法作为一种工业规模的生产工艺是非常有利的。